Login to Your Account



Cydan Accelerator Using $16M to Boost Orphan Drug Players

By Randy Osborne
Staff Writer

Thursday, April 11, 2013
Backed by $16 million from investors that include Pfizer Inc.'s venture arm, a new orphan drug accelerator called Cydan LLC aims to spin out as many as five new companies in the first four years.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription